Skip to main content
. 2017 Mar 23;8(21):34971–34979. doi: 10.18632/oncotarget.16496

Figure 3. 8β-VE2 reduces cell survival and induces apoptosis in different stages of prostate cancer.

Figure 3

(A and B) VCaP rev, (C and D) VCaP, and (E and F) VCaP AA cells were treated with DMSO, 5 μM 8β-VE2, or 25 μM 8β-VE2 and (A, C, E) cell survival and (B, D, F) apoptosis were measured 24, 48, and 72 h after the start of treatment. All three VCaP cell populations showed a downregulated cell survival rate compared with that of control cells. In addition, induction of apoptosis could be observed in all VCaP populations. The data represent the mean±s.d. of three independent experiments, which were performed in duplicate. * P<0.05, ** P<0.01, *** P<0.0001 compared with DMSO control.